Cairo Pharmaceuticals results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit246 millionEGP · +153.5% vs the same period a year earlier
Total assets1.52 billionEGP · +20.1% vs the same period a year earlier
Shareholders' equity832 millionEGP · +21.3% vs the same period a year earlier
Operating cash flow263 millionEGP · +197.0% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q3 2024 was about 246 million EGP, up +153.5% from 97.09 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 1.52 billion EGP, and shareholders' equity about 832 million EGP.
- Operating cash flow for Q3 2024 was positive at 263 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit246 million97.09 million+153.5%
Gross profit533 million242 million+120.0%
Total assets1.52 billion1.26 billion+20.1%
Total liabilities683 million575 million+18.8%
Shareholders' equity832 million686 million+21.3%
Total liabilities and equity1.52 billion1.26 billion+20.1%
Operating cash flow263 million88.53 million+197.0%
Investing cash flow-232 million-76.14 million−204.1%
Financing cash flow-2.41 million15.13 million−116.0%
Net change in cash28.9 million27.51 million+5.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy